A new paper describes a novel method, using a specific molecule to engage T cell receptors and the virus receptor, the angiotensin-converting enzyme 2, at the same time.
For more than two decades, University of Alabama at Birmingham researcher Susan Bellis, Ph.D., has studied how the addition of sialic acid to various proteins increases cancer resistance and oncogenicity.